Released Oct 26, 2017, after the close
10-Q filed Nov 2, 2017, 33 days after period end · 0001171843-17-006564
Q3 2017 · 10-Q
Revenue$18.72M$18.72M −25.2% vs Q3 2016−1.3% vs Q2 2017
Net Income-$417.00K-$417.00K N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.01-$0.01 N/M vs Q3 2016N/M vs Q2 2017
Gross Profit$9,500,000−18.7%
Operating Income-$390,000N/M
Operating Cash Flowderived$2,131,000−38.1%
Free Cash Flowderived$1,891,000—
Margins · derived
Gross margin50.8%+4.0 pt vs Q3 2016
Operating margin-2.1%+1.2 pt vs Q3 2016
Net margin-2.2%+4.3 pt vs Q3 2016
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $18.72M | $25.01M | $25.73M | $25.45M |
| Net Income | -$417.00K | -$1.64M | -$847.00K | $633.00K |
| EPS Diluted | -$0.01 | -$0.05 | -$0.02 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR